Pembrolizumab Plus Cabozantinib Elicits Responses in Recurrent HNSCC

home / oncclub / pembrolizumab-plus-cabozantinib-elicits-responses-in-recurrent-hnscc

Nabil F. Saba, MD, FACP, discusses data from a phase 2 trial (NCT03468218), which showed that pembrolizumab (Keytruda) plus cabozantinib (Cabometyx) elicited an overall response rate of 45.2% in patients with recurrent metastatic head and neck squamous cell carcinoma.

Nabil Saba, MD, FACP

Dr. Saba on the Investigation of Pembrolizumab Plus Cabozantinib in HNSCC

November 2nd 2022

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.

Nabil F. Saba, MD

Pembrolizumab Plus Cabozantinib Improves ORR in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

November 8th 2022

A doublet regimen comprised of pembrolizumab and cabozantinib elicited encouraging responses in patients with recurrent metastatic head and neck squamous cell carcinoma, meeting the primary end point of a phase 2 trial.

Nabil F. Saba, MD, FACP

Pembrolizumab/Cabozantinib Combo Shows Promising Clinical Benefit in Recurrent Metastatic HNSCC

November 9th 2022

Nabil F. Saba, MD, FACP, expanded on efficacy data from a phase 2 trial investigating pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma and current challenges and safety concerns in selecting patients for evaluation.